Announces oversubscribed private placement of u.s. $150 million

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement (the “private placement”) of 348,837,210 common shares in the capital of the company (the “common shares”) at a price of u.s.$0.43 per common share representing a premium.
CYBN Ratings Summary
CYBN Quant Ranking